Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05661942 · ClinicalTrials.gov registry record · Phase 4
Diltiazem in the Treatment of Atrial Fibrillation or Atrial Flutter With Rapid Ventricular Rate
A Phase 4 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 4
- Development phase
- 92
- Enrollment target
NCT05661942 is a Phase 4 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 92 participants.
The verdict
NCT05661942, a Phase 4 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 92 participants
- Enrollment target
Study Summary
The purpose of this study is to see how well calcium pre-treatment works for decreasing incidence of drug-induced hypotension after diltiazem administration for treatment of atrial flutter with rapid ventricular rate.
Interventions
- OTHER Placebo
- DRUG Calcium pre-treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2022-11-30 |
| Est. Completion | 2024-11-20 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05661942
The ClinicalTrials.gov registry entry for NCT05661942 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05661942 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05661942 about?
NCT05661942 is a clinical study titled "Diltiazem in the Treatment of Atrial Fibrillation or Atrial Flutter With Rapid Ventricular Rate". The purpose of this study is to see how well calcium pre-treatment works for decreasing incidence of drug-induced hypotension after diltiazem administration for treatment of atrial flutter with rapid ventricular rate.
What is the current status of trial NCT05661942?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 92 participants. The study started on 2022-11-30. Estimated completion is 2024-11-20.
What interventions are being tested in trial NCT05661942?
The interventions under investigation include: Placebo (OTHER), Calcium pre-treatment (DRUG).
Who is sponsoring clinical trial NCT05661942?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.